Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Sensitive quantitative IgD assay increases progression-free survival prediction accuracy in IgD plasma cell myeloma

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: The PFS of IgD myeloma patients stratified by optimizing response system (sCR 39 vs.CR 29 vs.


  1. Jancelewicz Z, Takatsuki K, Sugai S, Pruzanski W. IgD multiple myeloma. Review of 133 cases. Arch Intern Med. 1975;135:87–93.

    Article  CAS  Google Scholar 

  2. Reece DE, Vesole DH, Shrestha S, Zhang MJ, Perez WS, Dispenzieri A, et al. Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. Clin Lymphoma Myeloma Leuk. 2010;10:458–63.

    Article  Google Scholar 

  3. Rowe DS, Fahey JL. A new class of human immunoglobulins. I. A unique myeloma protein. J Exp Med. 1965;121:171–84.

    Article  CAS  Google Scholar 

  4. Blade J, Lust JA, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol. 1994;12:2398–404.

    Article  CAS  Google Scholar 

  5. Liu J, Hu X, Jia Y, Lu J, Lee JH, Kim K, et al. Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN). Leukemia. 2021;35:1797–802.

    Article  Google Scholar 

  6. Zagouri F, Kastritis E, Symeonidis AS, Giannakoulas N, Katodritou E, Delimpasi S, et al. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. Eur J Haematol. 2014;92:308–12.

    Article  CAS  Google Scholar 

  7. Wechalekar A, Amato D, Chen C, Keith Stewart A, Reece D. IgD multiple myeloma-a clinical profile and outcome with chemotherapy and autologous stem cell transplantation. Ann Hematol. 2005;84:115–7.

    Article  Google Scholar 

  8. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.

    Article  Google Scholar 

  9. Morris C, Drake M, Apperley J, Iacobelli S, van Biezen A, Bjorkstrand B, et al. Efficacy and outcome of autologous transplantation in rare myelomas. Haematologica. 2010;95:2126–33.

    Article  Google Scholar 

  10. Pandey S, Kyle RA. Unusual myelomas: a review of IgD and IgE variants. Oncol (Williston Park). 2013;27:798–803.

    Google Scholar 

  11. Vladutiu AO. Immunoglobulin D: properties, measurement, and clinical relevance. Clin Diagn Lab Immunol. 2000;7:131–40.

    Article  CAS  Google Scholar 

  12. Schmielau J, Teschendorf C, Konig M, Schmiegel W, Graeven U. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma. Leuk Lymphoma. 2005;46:567–9.

    Article  CAS  Google Scholar 

  13. Bemelmans RH, van Toorn DW, van Leeuwen L, Schaar CG. Long-term complete remission in IgD-myeloma. Eur J Haematol. 2006;76:339–41.

    Article  CAS  Google Scholar 

  14. Farnault L, Chebrek S, Souteyrand P, Sebahoun G, Costello R. Recurrent superior vena cava syndrome caused by IgD multiple myeloma. Ann Hematol. 2012;91:1977–8.

    Article  CAS  Google Scholar 

  15. He J, Zhang H, Jiang H, Zeng T, Chang H, Hou J. [The significance of serum IgD quantitation for evaluation of clinical efficacy in IgD multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi. 2016;37:288–91.

    Article  Google Scholar 

Download references


RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Center. YL and RPG was supported by the Ministry of Science and Technology of China (84000–51200002).


Supported, in part, by grants from the National Natural Science Foundation of China (NFSC 82170198 and NFSC 81870164) and Clinical Research Plan of SHDC.

Author information

Authors and Affiliations



JD, JH and YL designed the study; JL and JL collected and analyzed the data; WQ. YJ, HH and XY treated the subjects; WJC and RPG analyzed the data and revised the typescript. All authors approved the final typescript and agreed to submit for publication.

Corresponding authors

Correspondence to Yang Liang, Jian Hou or Juan Du.

Ethics declarations

Competing interests

RPG is a consultant to NexImmune Inc. Nanexa Pharma Ascentage Pharm Group and Antengene Biotech LLC, Medical Director of FFF Enterprises Inc.; Partner in AZAC Inc.; Board of Directors of Russian Foundation for Cancer Research Support and Scientific Advisory Board: StemRad Ltd.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, J., Lu, J., Qiang, W. et al. Sensitive quantitative IgD assay increases progression-free survival prediction accuracy in IgD plasma cell myeloma. Leukemia (2022).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI:


Quick links